Innoviva Inc (INVA)

16.90 -0.19  -1.11% NASDAQ Nov 26, 12:59 16.90 0.00  0.00% After-Hours: 13:59 USD
View Full Chart
Price Chart
View All INVA News


View All Events


Date Type Description
02/03/2022 Earnings Results Q4 2021 Earnings Results
10/27/2021 Earnings Results Q3 2021 Earnings Results
07/28/2021 Earnings Results Q2 2021 Earnings Results
05/14/2021 10:00 EST AGM 2020 Annual General Meeting
04/28/2021 Earnings Results Q1 2021 Earnings Results
02/03/2021 Earnings Results Q4 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Ratings & Reports



  • Description: Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.
  • URL:
  • Investor Relations URL:
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Feb. 03, 2022
  • Last Earnings Release: Oct. 27, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: Sep. 08, 2015

Top Fund Holders

Symbol Name Weighting
F000016H5Q FT Automated Quantitative Analysis 22 CA 5.91%
F00001CP3V FT Automated Quantitative Analysis 23 CA 4.90%
PHSRX Putnam Global Health Care R 3.02%
ACTV LeaderShares® Activist Leaders® ETF 2.96%
HRSGX Harbor Small Cap Growth Admin 2.41%
JMCRX James Micro Cap 2.11%
CALF Pacer US Small Cap Cash Cows 100 ETF 1.54%
BOGIX SGI Small Cap Growth Fd Instl 1.00%
EES WisdomTree US SmallCap Earnings ETF 0.64%
IHE iShares US Pharmaceuticals ETF 0.37%





Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{}} No credit card required.

Already a subscriber? Sign in.